1. Home
  2. H vs GH Comparison

H vs GH Comparison

Compare H & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyatt Hotels Corporation

H

Hyatt Hotels Corporation

HOLD

Current Price

$164.37

Market Cap

14.6B

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$88.96

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
H
GH
Founded
1957
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.6B
13.3B
IPO Year
2009
2018

Fundamental Metrics

Financial Performance
Metric
H
GH
Price
$164.37
$88.96
Analyst Decision
Buy
Strong Buy
Analyst Count
15
19
Target Price
$179.53
$119.79
AVG Volume (30 Days)
676.7K
2.1M
Earning Date
04-30-2026
05-07-2026
Dividend Yield
0.37%
N/A
EPS Growth
N/A
6.74
EPS
N/A
N/A
Revenue
$4,685,000,000.00
$982,021,000.00
Revenue This Year
$110.63
$33.30
Revenue Next Year
$7.01
$28.27
P/E Ratio
N/A
N/A
Revenue Growth
5.78
32.88
52 Week Low
$108.24
$36.36
52 Week High
$180.53
$120.74

Technical Indicators

Market Signals
Indicator
H
GH
Relative Strength Index (RSI) 58.13 49.73
Support Level $137.21 $82.33
Resistance Level $171.80 $90.28
Average True Range (ATR) 5.39 5.35
MACD 0.69 0.50
Stochastic Oscillator 55.54 58.65

Price Performance

Historical Comparison
H
GH

About H Hyatt Hotels Corporation

Hyatt is an operator of owned (2% of total rooms) and managed and franchised (98%) properties across about 35 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 45% for the US, 31% rest of world, and 24% Asia-Pacific.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: